Open Access Peer-reviewed Case Report

Three first cases of Meige syndrome in Central Africa

Article Sidebar

Download PDF
Submitted   Oct 9, 2022
Published   Dec 23, 2022
Issue    Vol 4 No 1 (2022)
DOI   10.25082/AGPM.2022.01.005

Views

998

Downloads

660

Citations

PlumX Metrics

Main Article Content

Marcellin Bugeme
Faculty of Medicine, University of Lubumbashi, Lubumbashi, Democratic Republic of the Congo
Yacouba Kaba
Centre Hospitalier Universitaire de Brazzaville, Republic of Congo
Franck Shongo Omanjelo
Faculty of Medicine, University of Lubumbashi, Lubumbashi, Democratic Republic of the Congo
Jacques Mbaz Musung
Faculty of Medicine, University of Lubumbashi, Lubumbashi, Democratic Republic of the Congo
Sarah Kilumba Numbi
Faculty of Medicine, University of Lubumbashi, Lubumbashi, Democratic Republic of the Congo
Olivier Mukuku corresponding author
Higher Institute of Medical Techniques, Lubumbashi, Democratic Republic of the Congo
Emmanuel Kiyana Muyumba
Faculty of Medicine, University of Lubumbashi, Lubumbashi, Democratic Republic of the Congo
Dirk E. Teuwen
[1] Department of Neurology, University Hospital, Ghent, Belgium; [2] Department of Neurology, Institute of Neuroscience, Ghent University, Belgium

Abstract

Meige syndrome (MS) is a rare type of focal dystonia characterized by unintentional bilateral activity in facial and mandibular muscles in combination with blepharospasm (spasm in the orbicular muscle). Often unknown cause, MS can be primary (idiopathic) or secondary (to medications or brain degenerative pathologies). Its treatment is based in most cases on botulinum toxin injections, not available in our environment. Nevertheless, clonazepam treatment has allowed us to improve the symptoms of our patients. We report MS in three patients, all with no particular history of consulting for involuntary facial movements. The diagnosis of MS was essentially based on the clinical picture. After treatment with clonazepam, the clinical course in all three patients was marked by the almost complete disappearance of these abnormal movements. In all cases, clinical progress was favorable with an average decline of 12 months; no recidivism was noted.

Keywords
Meige syndrome, abnormal movements, clonazepam, Lubumbashi

Article Details

How to Cite
Bugeme, M., Kaba, Y., Omanjelo, F. S., Musung, J. M., Numbi, S. K., Mukuku, O., Muyumba, E. K., & Teuwen, D. E. (2022). Three first cases of Meige syndrome in Central Africa. Advances in General Practice of Medicine, 4(1), 67-70. https://doi.org/10.25082/AGPM.2022.01.005
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

References

  1. LeDoux MS. Meige syndrome: what’s in a name? Parkinsonism & related disorders, 2009, 15(7): 483-489. https://doi.org/10.1016/j.parkreldis.2009.04.006
  2. Béreau M and Tatu L. Brueghel Syndrome or Meige Syndrome? Two Sides of a Same Disease. Neurologic-Psychiatric Syndromes in Focus-Part I, 2018, 41: 98-103. https://doi.org/10.1159/000475701
  3. Martinez-Castrillo JC, Mariscal A and Garcia-Ruiz P. Ancient representation of Meige’s syndrome in the Moche culture in the pre-Columbian Peru. Movement Disorders, 2010, 25(4): 405-406. https://doi.org/10.1002/mds.22954
  4. Gilbert GJ. Brueghel syndrome: its distinction from Meige syndrome. Neurology, 1996, 46(6): 1767-1769. https://doi.org/10.1212/WNL.46.6.1767
  5. Sellal F and Frismand S. Cervico-facial dystonia as depicted in sculpture before its scientific description. Revue Neurologique, 2019, 175(3): 198-200. https://doi.org/10.1016/j.neurol.2018.05.006
  6. Jahngir MU, Ameer MA and Patel BC. Meige Syndrome. In: StatPearls. StatPearls Publishing, Treasure Island (FL), 2021, PMID: 30020730.
  7. Teng X, Qu Q, Shu Y, et al. Genetic screening in patients of Meige syndrome and blepharospasm. Neurological Sciences, 2022, 43(6): 3683-3694. https://doi.org/10.1007/s10072-022-05900-8
  8. Nguyen K, Hoegerl C. A Case of Meige Syndrome Treated With Baclofen. Cureus, 2020, 12(9): e10570. https://doi.org/10.7759/cureus.10570
  9. Møller E, Werdelin L M, Bakke M, et al. Treatment of perioral dystonia with botulinum toxin in 4 cases of Meige’s syndrome. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 2003, 96(5): 544-549. https://doi.org/10.1016/j.tripleo.2003.08.011
  10. Ma H, Qu J, Ye L, et al. Blepharospasm, oromandibular dystonia, and meige syndrome: clinical and genetic update. Frontiers in Neurology, 2021, 12: 630221. https://doi.org/10.3389/fneur.2021.630221
  11. Debadatta M and Mishra AK. Meige’s syndrome: Rare neurological disorder presenting as conversion disorder. Indian Journal of Psychological Medicine, 2013, 35(3): 317-318. https://doi.org/10.4103/0253-7176.119493
  12. Abaroa L and Garretto NS. Meige’s syndrome. Reference Module in Neuroscience and Biobehavioral Psychology, 2017, 1-5. https://doi.org/10.1016/B978-0-12-809324-5.00666-0
  13. Vingerhoets F, Russmann H, Carruzzo A, et al. Mouvements anormaux (dystonie, ath´etose, chor´ee, ballisme). EMC-Neurologie, 2004, 1(1): 3-41. https://doi.org/10.1016/j.emcn.2003.10.006
  14. Hattori H, Yoshikawa F, Sato H, et al. Spasmodic dysphonia in Meige syndrome responding to clonazepam. Internal Medicine, 2011, 50(18): 2061-2062. https://doi.org/10.2169/internalmedicine.50.5812
  15. Mauriello JA, Dhillon S, Leone T, et al. Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years. British Journal of Ophthalmology, 1996, 80(12): 1073-1076. https://doi.org/10.1136/bjo.80.12.1073
  16. Benrouma H, Kraoua I, Klaa H, et al. Les aspects cliniques et th´erapeutiques des dystonies en Tunisie. Revue Neurologique, 2013, 169: 47-42. https://doi.org/10.1016/j.neurol.2012.01.586
  17. Goldberg MA and Dorman JD. Intention myoclonus: successful treatment with clonazepam. Neurology, 1976, 26(1): 24-24. https://doi.org/10.1212/WNL.26.1.24